TITLE

HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin

AUTHOR(S)
Ruggeri, Rosaria M.; Campennì, Alfredo; Giuffrè, Giuseppe; Giovanella, Luca; Siracusa, Massimiliano; Simone, Angela; Branca, Giovanni; Scarfì, Rosa; Trimarchi, Francesco; Ieni, Antonio; Tuccari, Giovanni
PUB. DATE
December 2016
SOURCE
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2040
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The Epidermal Growth Factor Receoptor (EGFR) family member human epidermal growth factor receptor 2 (HER2) is overexpressed in many human epithelial malignancies, representing a molecular target for specific anti-neoplastic drugs. Few data are available on HER2 status in differentiated thyroid cancer (DTC). The present study was aimed to investigate HER2 status in sporadic cancers of follicular cell origin to better clarify the role of this receptor in the stratification of thyroid cancer. By immunohistochemistry and fluorescence in-situ hybridization, HER2 expression was investigated in formalin-fixed paraffin-embedded surgical specimens from 90 DTC patients, 45 follicular (FTC) and 45 papillary (PTC) histotypes. No HER2 immunostaining was recorded in background thyroid tissue. By contrast, overall HER2 overexpression was found in 20/45 (44%) FTC and 8/45 (18%) PTC, with a significant difference between the two histotypes (p = 0.046). Five of the six patients who developed metastatic disease during a median nine-year follow-up had a HER2-positive tumor. Therefore, we suggest that HER2 expression may represent an additional aid to identify a subset of patients who are characterized by a worse prognosis and are potentially eligible for targeted therapy.
ACCESSION #
120516864

 

Related Articles

  • Expressions of CK-19, NF-κB, E-Cadherin, β-Catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. Sethi, Kruttibas; Sarkar, Siddik; Das, Subhasis; Rajput, Shashi; Mazumder, Abhijit; Roy, Bhaskar; Patra, Susmita; Mohanty, Biswanarayan; El-Naggar, Adel K.; Mandal, Mahitosh // Journal of Experimental Therapeutics & Oncology;2011, Vol. 9 Issue 3, p187 

    Immunohistochemical markers have been proposed for thyroid cancer diagnosis and prognostic studies. Immunohistochemical analysis of CK-19, NF-κB, β-catenin, E-cadherin and EGFR were done to evaluate their diagnostic and prognostic efficiencies in eighty eight cancer specimen (PTC-52,...

  • miR-200 Regulates Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer via EGF/EGFR Signaling. Xue, Lei; Su, Dongyue; Li, Dan; Gao, Wei; Yuan, Rongrong; Pang, Wuyan // Cell Biochemistry & Biophysics;May2015, Vol. 72 Issue 1, p185 

    This study was set to study the molecular mechanism underlying how miR-200 regulates EGF/EGFR signaling to involve in epithelial-mesenchymal transition (EMT) in anaplastic thyroid cancer (ATC) cells. Loss-of-function experiments of EGFR silencing by siRNA transfection was performed. Transfection...

  • In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. de Boer, Esther; Warram, Jason M.; Tucker, Matthew D.; Hartman, Yolanda E.; Moore, Lindsay S.; de Jong, Johannes S.; Chung, Thomas K.; Korb, Melissa L.; Zinn, Kurt R.; van Dam, Gooitzen M.; Rosenthal, Eben L.; Brandwein-Gensler, Margaret S. // Scientific Reports;7/3/2015, p10169 

    Anti-EGFR (epidermal growth factor receptor) antibody based treatment strategies have been successfully implemented in head and neck squamous cell carcinoma (HNSCC). Unfortunately, predicting an accurate and reliable therapeutic response remains a challenge on a per-patient basis. Although...

  • The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy. Yang, Yanqin; Xuan, Jize; Yang, Zhiqiang; Han, Anqin; Xing, Ligang; Yue, Jinbo; Hu, Man; Yu, Jinming // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1448 

    Epidermal growth factor receptor (EGFR) was expressed widely in NPC. The aim of this study was to investigate the difference of expression of EGFR and Ki67 in primary and recurrence of NPC to supply a micro-evidence of anti-EGFR targeted maintenance therapy for NPC. A retrospective review of 40...

  • Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs. Torino, Francesco; Barnabei, Agnese; Paragliola, Rosamaria; Baldelli, Roberto; Appetecchia, Marialuisa; Corsello, Salvatore Maria // Thyroid;Nov2013, Vol. 23 Issue 11, p1345 

    Background: Several of the currently used anticancer drugs may variably affect thyroid function, with impairment ranging from modified total but not free concentration of thyroid hormones to overt thyroid disease. Summary: Cytotoxic agents seem to alter thyroid function in a relatively small...

  • VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in Medullary Thyroid Carcinoma. Mancikova, Veronika; Inglada-Pérez, Lucía; Curras-Freixes, Maria; de Cubas, Aguirre A.; Gómez, Álvaro; Letón, Rocío; Kersten, Iris; Leandro-García, Luis Javier; Comino-Méndez, Iñaki; Apellaniz-Ruiz, María; Sánchez, Lara; Cascón, Alberto; Sastre-Marcos, Julia; García, Juan F.; Rodríguez-Antona, Cristina; Robledo, Mercedes // Thyroid;Aug2014, Vol. 24 Issue 8, p1251 

    Background: Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results in medullary thyroid carcinoma (MTC) patients. However, the considerable variability in patient response to treatment with TKIs remains largely unexplained. There is evidence that it could be due, at least in...

  • Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Moreno Garcia, V; Thavasu, P; Blanco Codesido, M; Molife, L R; Vitfell Pedersen, J; Puglisi, M; Basu, B; Shah, K; Iqbal, J; de Bono, J S; Kaye, S B; Banerji, U // British Journal of Cancer;11/20/2012, Vol. 107 Issue 11, p1797 

    Background:We investigated the association between skin rash and plasma creatine kinase (CK) levels in oncology phase I trials.Methods:We analysed data from 295 patients treated at our institution within 25 phase I trials which included CK measurements in the protocol. Trials involved drugs...

  • Erlotinib/gefitinib.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p91 

    The article presents case studies involving seven patients who developed hepatotoxicity after being treated with gefitinib for advanced epidermal growth factor receptor (EGFR) positive non-small cell lung cancer. It reveals that two patients have developed hepatotoxicity during erlotinib...

  • Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. Spector, Neil L.; Robertson, Faith C.; Bacus, Sarah; Blackwell, Kimberly; Smith, Deborah A.; Glenn, Kelli; Cartee, Leanne; Harris, Jennifer; Kimbrough, Carie L.; Gittelman, Mark; Avisar, Eli; Beitsch, Peter; Koch, Kevin M. // PLoS ONE;11/16/2015, Vol. 10 Issue 11, p1 

    Purpose: The paradigm shift in cancer treatment from cytotoxic drugs to tumor targeted therapies poses new challenges, including optimization of dose and schedule based on a biologically effective dose, rather than the historical maximum tolerated dose. Optimal dosing is currently determined...

  • Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. Li, Gordon; Mitra, Siddhartha; Monje, Michelle; Henrich, Kristy; Bangs, C.; Nitta, Ryan; Wong, Albert // Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p395 

    Despite numerous clinical trials over the past 2 decades, the overall survival for children diagnosed with diffuse intrinsic pontine glioma (DIPG) remains 9-10 months. Radiation therapy is the only treatment with proven effect and novel therapies are needed. Epidermal growth factor receptor...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics